Terms: = Pancreatic cancer AND MAP2K2, MEK2, 5605, ENSG00000126934, P36507, MKK2, MAPKK2, PRKMK2 AND Treatment
14 results:
1. Development and validation of cuproptosis-related lncRNAs associated with pancreatic cancer immune microenvironment based on single-cell.
Sun Y; Yao L; Man C; Gao Z; He R; Fan Y
Front Immunol; 2023; 14():1220760. PubMed ID: 37822927
[TBL] [Abstract] [Full Text] [Related]
2. Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: a case report.
Ardalan B; Azqueta JI; England J; Eatz TA
Cold Spring Harb Mol Case Stud; 2021 Oct; 7(5):. PubMed ID: 34667063
[TBL] [Abstract] [Full Text] [Related]
3. MEK/ERK Signaling in β-Cells Bifunctionally Regulates β-Cell Mass and Glucose-Stimulated Insulin Secretion Response to Maintain Glucose Homeostasis.
Ikushima YM; Awazawa M; Kobayashi N; Osonoi S; Takemiya S; Kobayashi H; Suwanai H; Morimoto Y; Soeda K; Adachi J; Muratani M; Charron J; Mizukami H; Takahashi N; Ueki K
Diabetes; 2021 Jul; 70(7):1519-1535. PubMed ID: 33906910
[TBL] [Abstract] [Full Text] [Related]
4. Role of exosomal microRNA-125b-5p in conferring the metastatic phenotype among pancreatic cancer cells with different potential of metastasis.
Wu M; Tan X; Liu P; Yang Y; Huang Y; Liu X; Meng X; Yu B; Wu Y; Jin H
Life Sci; 2020 Aug; 255():117857. PubMed ID: 32470446
[TBL] [Abstract] [Full Text] [Related]
5. Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine.
Ikeda M; Ioka T; Fukutomi A; Morizane C; Kasuga A; Takahashi H; Todaka A; Okusaka T; Creasy CL; Gorman S; Felitsky DJ; Kobayashi M; Zhang F; Furuse J
Cancer Sci; 2018 Jan; 109(1):215-224. PubMed ID: 29121415
[TBL] [Abstract] [Full Text] [Related]
6. A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors.
Kasuga A; Nakagawa K; Nagashima F; Shimizu T; Naruge D; Nishina S; Kitamura H; Kurata T; Takasu A; Fujisaka Y; Okamoto W; Nishimura Y; Mukaiyama A; Matsushita H; Furuse J
Invest New Drugs; 2015 Oct; 33(5):1058-67. PubMed ID: 26259955
[TBL] [Abstract] [Full Text] [Related]
7. Trametinib: first global approval.
Wright CJ; McCormack PL
Drugs; 2013 Jul; 73(11):1245-54. PubMed ID: 23846731
[TBL] [Abstract] [Full Text] [Related]
8. Zonula occludens-1 (ZO-1) redistribution is involved in the regulation of cell dissociation in pancreatic cancer cells.
Tan X; Egami H; Ishikawa S; Kurizaki T; Hirota M; Ogawa M
Dig Dis Sci; 2005 Aug; 50(8):1402-9. PubMed ID: 16110828
[TBL] [Abstract] [Full Text] [Related]
9. Arrangement of expression and distribution of tight junction protein claudin-1 in cell dissociation of pancreatic cancer cells.
Tan X; Egami H; Ishikawa S; Kurizaki T; Nakagawa M; Hirota M; Ogawa M
Int J Oncol; 2004 Dec; 25(6):1567-74. PubMed ID: 15547692
[TBL] [Abstract] [Full Text] [Related]
10. Analysis of invasion-metastasis mechanism in pancreatic cancer: involvement of tight junction transmembrane protein occludin and MEK/ERK signal transduction pathway in cancer cell dissociation.
Tan X; Tamori Y; Egami H; Ishikawa S; Kurizaki T; Takai E; Hirota M; Ogawa M
Oncol Rep; 2004 May; 11(5):993-8. PubMed ID: 15069537
[TBL] [Abstract] [Full Text] [Related]
11. Relationship between the expression of extracellular signal-regulated kinase 1/2 and the dissociation of pancreatic cancer cells: Involvement of ERK1/2 in the dissociation status of cancer cells.
Tan X; Egami H; Ishikawa S; Kurizaki T; Tamori Y; Takai E; Hirota M; Ogawa M
Int J Oncol; 2004 Apr; 24(4):815-20. PubMed ID: 15010817
[TBL] [Abstract] [Full Text] [Related]
12. Involvement of the mitogen-activated protein kinase kinase 2 in the induction of cell dissociation in pancreatic cancer.
Tan X; Egami H; Kamohara H; Ishikawa S; Kurizaki T; Yoshida N; Tamori Y; Takai E; Hirota M; Ogawa M
Int J Oncol; 2004 Jan; 24(1):65-73. PubMed ID: 14654942
[TBL] [Abstract] [Full Text] [Related]
13. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK).
Allen LF; Sebolt-Leopold J; Meyer MB
Semin Oncol; 2003 Oct; 30(5 Suppl 16):105-16. PubMed ID: 14613031
[TBL] [Abstract] [Full Text] [Related]
14. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets.
Calhoun ES; Jones JB; Ashfaq R; Adsay V; Baker SJ; Valentine V; Hempen PM; Hilgers W; Yeo CJ; Hruban RH; Kern SE
Am J Pathol; 2003 Oct; 163(4):1255-60. PubMed ID: 14507635
[TBL] [Abstract] [Full Text] [Related]
